Notice: This company has been marked as potentially delisted and may not be actively trading. Immunomedics (IMMU) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Gilead Sciences Tops Estimates in Q3November 8, 2024 | fool.comGilead Sciences, Inc. (GILD) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comGilead Sciences Announces Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comGilead Sciences (GILD) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comGilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ...November 7, 2024 | finance.yahoo.comGilead Sciences Shows Strong Q3 Results Amid Strategic InitiativesNovember 7, 2024 | markets.businessinsider.comGilead to pull drug that had won conditional approval for bladder cancerOctober 18, 2024 | bizjournals.comAntibody Drug Conjugates Market Size Potential to Reach USD 39 Billion by 2032 By IMIR Market Research Pvt. Ltd.October 7, 2024 | finance.yahoo.comTROP2 Antibody Market & Clinical Trials Report to 2029: Insight By Company, Country, Indication & Phase - ResearchAndMarkets.comAugust 23, 2024 | businesswire.comNew treatment option for endometrial cancer shows promise in phase II trialAugust 1, 2024 | msn.comGilead Sciences's Options Frenzy: What You Need to KnowJuly 31, 2024 | benzinga.comA Look At Gilead Sciences After Its Recent WeaknessJuly 27, 2024 | seekingalpha.comDecoding Gilead Sciences Inc (GILD): A Strategic SWOT InsightMay 9, 2024 | finance.yahoo.comGilead Sciences Unusual Options Activity For May 06May 6, 2024 | benzinga.comGilead cuts jobs, trims drugs amid deeper biopharma pullbackMay 3, 2024 | bizjournals.comGilead Sciences (GILD) Q1 2024 Earnings Call TranscriptApril 25, 2024 | msn.comGilead Sciences Posts Higher 1Q Sales, Swings to Loss on ChargesApril 25, 2024 | marketwatch.comGilead posts quarterly loss on acquisition charge, revenue rises 5%April 25, 2024 | msn.comThe Analyst Verdict: Gilead Sciences In The Eyes Of 12 ExpertsApril 19, 2024 | markets.businessinsider.comWhat the Options Market Tells Us About Gilead SciencesApril 18, 2024 | benzinga.comNorthStar Appoints Peter Pfreundschuh to Board of ManagersApril 15, 2024 | finance.yahoo.comGilead bets on ‘trispecifics’ in latest cancer drug dealMarch 6, 2024 | finance.yahoo.comAbingworth invests in Trodelvy development in deal with GileadFebruary 29, 2024 | finance.yahoo.comGilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to PipelineFebruary 13, 2024 | msn.comGilead Sciences, Inc.: Gilead: Maintaining Our $97 Fair Value Estimate as CymaBay Acquisition Looks Like a Good FitFebruary 12, 2024 | finance.yahoo.comGilead to buy CymaBay in $4.3B deal for liver disease drugFebruary 12, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining $97 Fair Value Estimate as HIV and Oncology Catalysts ApproachFebruary 7, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Trodelvy Lung Cancer Data Disappoints, but No Changes to Our Fair Value EstimateJanuary 22, 2024 | finance.yahoo.comArvinas Appoints Jared Freedberg as General CounselJanuary 16, 2024 | finance.yahoo.comNeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial OfficerJanuary 9, 2024 | finance.yahoo.comGilead Sciences's Options: A Look at What the Big Money is ThinkingNovember 15, 2023 | benzinga.comA Closer Look at Gilead Sciences's Options Market DynamicsNovember 9, 2023 | benzinga.comGilead Sciences, Inc.: Gilead Earnings: Maintaining Our $97 FVE Following In-Line HIV and Oncology PerformanceNovember 8, 2023 | finance.yahoo.comDaily Digest: Slack CEO departs; Big East Bay battery factory opensNovember 6, 2023 | bizjournals.comGilead sues former CFO of Immunomedics to claw back $4 millionNovember 6, 2023 | bizjournals.comSpate of Deal News Juices Start of This Week's TradingOctober 29, 2023 | realmoney.thestreet.comUnraveling Gilead Sciences Inc's Dividend Performance and SustainabilitySeptember 14, 2023 | finance.yahoo.comAntibody Drug Conjugate (ADC) Markets, 2035August 24, 2023 | uk.finance.yahoo.com8 Undervalued Quality Healthcare StocksAugust 13, 2023 | morningstar.comGilead Sciences, Inc.: Gilead's HIV Dominance and Growing Oncology Portfolio Support a Wide MoatAugust 4, 2023 | finance.yahoo.comImmunomedics, Seattle Genetics Lead Biotech Movers on Deal NewsJuly 19, 2023 | thestreet.comLooking For Attractive Uncorrelated Returns in a Highly Uncertain Market? Consider Merger ArbitrageJuly 11, 2023 | finance.yahoo.comThe global Cell therapy Processing market Size during the period of 2023 to 2030 is expected grow at CAGR of 9.1%June 22, 2023 | marketwatch.comEuropean shares slip on US debt ceiling concernsMay 18, 2023 | msn.comASIA Japan leads the way, China feels the heatMay 17, 2023 | reuters.comFormer Immunomedics CFO pleads guilty to insider tradingMay 17, 2023 | msn.comNext Generation Antibody Therapeutics Market Size: Growth Dynamics from 2023 to 2031May 17, 2023 | marketwatch.comFuture of Antibody Drug Conjugate Market 2023: Active Key Players and Emerging Trends in Industry till 2030May 16, 2023 | marketwatch.com2030, Immunocytokines Market ResearchMay 15, 2023 | marketwatch.comChemotherapy Market Future Investments and Forecast Till 2030May 11, 2023 | marketwatch.com Get Immunomedics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin IMMU Media Mentions By Week IMMU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMU News Sentiment▼0.000.60▲Average Medical News Sentiment IMMU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMU Articles This Week▼00▲IMMU Articles Average Week Get Immunomedics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies REGN News Today ALNY News Today BIIB News Today UTHR News Today NBIX News Today INCY News Today BMRN News Today EXAS News Today EXEL News Today RGEN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMU) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunomedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMMU Stock Alerts